Subtype
Genitourinary System Carcinoma
CI-CAN-00000925Explore in graph →
1,501 active trials44 approved drugs143 evidence items
- NCIt
- C164141
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000925Explore in graph →
Clinical trials
4,919 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (758)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05931419 | High-Risk prostatE Cancer radiatiOn Versus surgERy(RECOVER) | recruiting | — | 837 | Comprehensive Cancer Centre The NetherlandsOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07023432 | Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC) | recruiting | Phase 2 | 78 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 |
| clinicaltrials |
| NCT07189403 | A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer | recruiting | Phase 1 | 40 | Daiichi SankyoINDUSTRY | 3 | May 22, 2026 | clinicaltrials |
| NCT07468903 | Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer | recruiting | N/A | 45 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07602010 | Comparison of CT and MR (VI-RADS) Imaging for Local Bladder Cancer Staging | recruiting | — | 150 | Oslo University HospitalOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06053658 | Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma | recruiting | Phase 2 | 48 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT06305299 | Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells | recruiting | Phase 1 | 27 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT03933670 | Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance | recruiting | Phase 2 | 60 | University of California, San FranciscoOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT05700461 | Drug Screening Using Novel IMD in Renal Cell Carcinoma | recruiting | Phase 1 | 20 | Oliver JonasOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT04472338 | Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study | recruiting | — | 450 | University of WashingtonOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT04969835 | A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours | recruiting | Phase 1 | 158 | Avacta Life Sciences LtdINDUSTRY | 2 | May 15, 2026 | clinicaltrials |
| NCT05627219 | Extending Prostate Genetic Awareness, Navigation, and Delivery: The EXPAND Network | recruiting | — | 30 | Thomas Jefferson UniversityOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07093801 | Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate Cancer | recruiting | — | 300 | Novartis PharmaceuticalsINDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT07244341 | A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC) | recruiting | Phase 1 | 60 | Daiichi SankyoINDUSTRY | 4 | May 15, 2026 | clinicaltrials |
| NCT07476001 | Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC | recruiting | Phase 2 | 12 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07589543 | Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer(EB-DUALNK-OV) | recruiting | Phase 1 / Phase 2 | 42 | Beijing BiotechINDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT05413850 | Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection | recruiting | Phase 1 / Phase 2 | 82 | Blue Earth Therapeutics LtdINDUSTRY | 5 | May 14, 2026 | clinicaltrials |
| NCT06733350 | Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance | recruiting | Phase 4 | 600 | Roswell Park Cancer InstituteOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07557225 | 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors | recruiting | N/A | 200 | Peking University First HospitalOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07400536 | A Clinical Study on the Treatment of LACC With Cadonilimab Combined With Chemotherapy Followed by CCRT | recruiting | Phase 3 | 378 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06852638 | CD70-targeted immunoPET Imaging of Malignant Cancers | recruiting | Phase 2 | 300 | RenJi HospitalOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT06879041 | A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 | 136 | AstraZenecaINDUSTRY | 3 | May 12, 2026 | clinicaltrials |
| NCT05284552 | Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer | recruiting | Phase 2 | 40 | University Hospital, LinkoepingOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT07571551 | Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell Carcinoma(TRIPLE-PATH) | recruiting | Phase 2 | 75 | Jinling Hospital, ChinaOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT04986423 | ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 2 | 200 | Zenith EpigeneticsINDUSTRY | 2 | May 8, 2026 | clinicaltrials |
| NCT05363280 | Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment | recruiting | Phase 2 | 80 | Advenchen Pharmaceuticals, LLC.INDUSTRY | 2 | May 8, 2026 | clinicaltrials |
| NCT06011499 | Internet-Based Lifestyle Intervention to Eradicate Obese Frailty in Prostate Cancer Survivors, iLIVE(iLIVE) | recruiting | N/A | 250 | OHSU Knight Cancer InstituteOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07087860 | Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers(RECIPE-B1) | recruiting | Phase 2 | 70 | Mayo ClinicOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07414940 | ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium(ACT-RESoLUTE) | recruiting | Phase 1 / Phase 2 | 60 | University College, LondonOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT03880422 | Nutrition and Exercise Interventions for Androgen Deprivation Therapy-Induced Obese Frailty in Elderly and Non-Elderly Survivors of Advanced Prostate Cancer | recruiting | N/A | 50 | Roswell Park Cancer InstituteOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT04053855 | Evaluation of Urinary Exosomes Presence From Clear Cell Renal Cell Carcinoma(PEP-C) | recruiting | — | 100 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT05049538 | Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers | recruiting | — | 1,000 | M.D. Anderson Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07504835 | GET FIT Together: Testing a Socially Enhanced Exercise Program in Older Men With Prostate Cancer | recruiting | N/A | 150 | OHSU Knight Cancer InstituteOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07555210 | Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy | recruiting | N/A | 25 | Jessica Mezzanotte SharpeOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT03713203 | PAGETEX® Photodynamic Therapy Device for the Treatment of Extra Mammary Paget's Disease of the Vulva (EMPV).(PAGETEX) | recruiting | N/A | 24 | University Hospital, LilleOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05125016 | A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer | recruiting | Phase 1 / Phase 2 | 228 | Regeneron PharmaceuticalsINDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT06466382 | OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy(OVPrecision) | recruiting | N/A | 60 | Swiss GO Trial GroupNETWORK | 1 | May 5, 2026 | clinicaltrials |
| NCT06616155 | Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 / Phase 2 | 20 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05551507 | IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer | recruiting | Phase 1 / Phase 2 | 150 | InxMed (Shanghai) Co., Ltd.INDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT06335667 | mpMRI Compared to Diagnostic TURBT in Patients With Suspected Muscle-Invasive Bladder Cancer | recruiting | N/A | 30 | University of California, IrvineOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05646485 | Bladder Cancer Screening Trial | recruiting | N/A | 1,000 | University of Texas Southwestern Medical CenterOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT02526368 | Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer | recruiting | Early Phase 1 | 80 | Ivan de Kouchkovsky, MDOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT05440760 | Using Virtual Reality Technology to Improve Patient Experience and Quality of Care During Brachytherapy | recruiting | N/A | 20 | University of ArkansasOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT06682728 | Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence | recruiting | Phase 2 | 23 | University of California, IrvineOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07241793 | Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)(TRAIN-UC-01) | recruiting | Phase 2 | 96 | Sun Yat-sen UniversityOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07413523 | Randomized Trial of stAndard of Care With or Without Metastases-directed Stereotactic Body Radiation Therapy in Patients Affected by Oligometastatic uRothelial carcinomA(ASTRA) | recruiting | N/A | 44 | Istituto Clinico HumanitasOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07451795 | SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC(SHARP) | recruiting | Phase 2 | 66 | Fudan UniversityOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT04878029 | Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer | recruiting | Phase 1 | 32 | Emory UniversityOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT05023265 | Assessment of Quality of Life and Outcomes in Patients With Primary Renal Cell Carcinoma Treated With SBRT(AQuOS-II) | recruiting | N/A | 70 | Sunnybrook Health Sciences CentreOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06413680 | A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body(BrILliance) | recruiting | Phase 1 / Phase 2 | 240 | Regeneron PharmaceuticalsINDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
Data updated 24 days agoSource updated May 22, 2026source: clinicaltrials